Comparison of plasma separation using centrifugation or filtration for MONET lipoprotein apheresis in patients with cardiovascular disease and severe dyslipidemia
- PMID: 35322939
- PMCID: PMC9790347
- DOI: 10.1111/1744-9987.13840
Comparison of plasma separation using centrifugation or filtration for MONET lipoprotein apheresis in patients with cardiovascular disease and severe dyslipidemia
Abstract
Introduction: Homozygous or severe heterozygous familial hypercholesterolemia and elevated lipoprotein(a) levels may be treated with membrane filtration. The MONET system (Fresenius Medical Care, Bad Homburg, Germany) involves plasma separation by centrifugation or filtration.
Methods: Whether the method of plasma separation affects lipoprotein lowering and treatment safety was investigated in a single-center retrospective study.
Results: The centrifugation-based plasma separation achieved a higher plasma flow and shorter time to treat 1 L of plasma (46.2 ± 8.6 min), than the filtration-based system (71.5 ± 40.0 min; p = 0.001). The mean reduction of LDL-cholesterol was 69% and 67% with centrifugation and filtration and was 75% for lipoprotein(a) with both plasma separation methods. A reduction of IgM by more than 60%, of albumin and total protein by approximately 20% and low frequency of side effects was observed.
Conclusions: The efficacy of lowering atherogenic lipoproteins was comparable with both plasma separation methods. Centrifugation was more time-efficient compared to filtration.
Keywords: LDL cholesterol; Lp(a); lipoprotein apheresis; plasma separation.
© 2022 The Authors. Therapeutic Apheresis and Dialysis published by John Wiley & Sons Australia, Ltd on behalf of International Society for Apheresis and Japanese Society for Apheresis.
Conflict of interest statement
Heinrich Prophet and Grit Waitz are/were full‐time employees at Nephrocare Rostock and Apheresis Center Rostock, Germany. Saynab Atiye and Adelheid Gauly are full‐time employees of Fresenius Medical Care, Bad Homburg, Germany.
Figures


Similar articles
-
Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.Cardiol J. 2019;26(6):669-679. doi: 10.5603/CJ.a2018.0100. Epub 2018 Sep 20. Cardiol J. 2019. PMID: 30234904 Free PMC article.
-
Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?Atheroscler Suppl. 2017 Nov;30:44-49. doi: 10.1016/j.atherosclerosissup.2017.05.005. Epub 2017 Jun 1. Atheroscler Suppl. 2017. PMID: 29096860 Review.
-
Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.J Clin Apher. 2021 Jun;36(3):370-378. doi: 10.1002/jca.21872. Epub 2021 Jan 2. J Clin Apher. 2021. PMID: 33386762
-
Low-density lipoprotein apheresis: an evidence-based analysis.Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 1. Ont Health Technol Assess Ser. 2007. PMID: 23074505 Free PMC article.
-
LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia.Transfus Sci. 1993 Jul;14(3):249-59. doi: 10.1016/0955-3886(93)90005-F. Transfus Sci. 1993. PMID: 10146336 Review.
Cited by
-
Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs.Int J Mol Sci. 2024 Dec 19;25(24):13597. doi: 10.3390/ijms252413597. Int J Mol Sci. 2024. PMID: 39769362 Free PMC article.
References
-
- Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta‐analysis. Circulation. 2020;141:1742–59. - PubMed
-
- Gudbjartsson DF, Thorgeirsson G, Sulem P, Helgadottir A, Gylfason A, Saemundsdottir J, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74:2982–94. - PubMed
-
- Jang AY, Han SH, Sohn IS, Oh PC, Koh KK. Lipoprotein(a) and cardiovascular diseases‐ revisited. Circ J. 2020;84:867–74. - PubMed
-
- Weingärtner O, Lütjohann D, Plösch T, Elsässer A. Individualized lipid‐lowering therapy to further reduce residual cardiovascular risk. J Steroid Biochem Mol Biol. 2017;169:198–201. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials